Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children’s Oncology Group

@article{Warren2005PhaseIT,
  title={Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children’s Oncology Group},
  author={Katherine Warren and Regina Jakacki and Brigitte C Widemann and Alberta A. Aikin and Madeleine Libucha and Roger I Packer and Gilbert Vezina and Gregory Reaman and Danielle R S Shaw and Mark D. Krailo and Cynthia R C Osborne and Jeffrey E. Cehelsky and David Caldwell and J. Stanwood and Seth Steinberg and Frank M Balis},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2005},
  volume={58},
  pages={343-347}
}
Backround: Lobradimil is a synthetic bradykinin analog that rapidly and transiently increases the permeability of the blood-brain barrier (BBB). The combination of lobradimil and carboplatin was studied in pediatric patients with primary brain tumors in a phase II trial, the primary endpoints of which were to estimate the response rate and time to disease progression. Patients and methods: Patients were stratified by histology into five cohorts: brainstem glioma, high-grade glioma, low-grade… CONTINUE READING